Thoracic SurgeryNCT07749456
Effects of Permissive Hypercapnia During Lung Surgery on Inflammatory Biomarkers in Serum and Bronchoalveolar Lavage Fluid
A study testing Allowed permissive hypercapnia in people with Thoracic Surgery, run by University of Nis.
Trial summary
The primary objective was to evaluate the effects of permissive hypercapnia on inflammatory biomarkers in bronchoalveolar lavage fluid and serum during one-lung ventilation. The secondary objective was to assess the influence of different ventilation modes on these inflammatory responses. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Thoracic Surgery
- What is being tested?
- Allowed permissive hypercapnia
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2015to 28 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Eligible participants were aged 18-85 years,
- classified as American Society of Anesthesiologists (ASA) physical status I-III, --scheduled for procedures expected to last at least 60 minutes, with anticipated OLV for the the majority of the intraoperative period.
Who cannot join
- body mass index (BMI) > 35 kg/m2;
- impaired pulmonary function (vital capacity of forced expiratory volume in 1 second (FEV1) < 50% of predicted values);
- chronic infection;
- intracranial hypertension;
- prior intracranial hemorrhage;
- presence of active extrapulmonary malignancy;
Show all 10Show fewer
- chronic pulmonary diseases (including chronic pneumonia, pneumoconiosis and silicosis);
- pulmonary hypertension;
- severe chronic obstructive pulmonary disease (COPD) with chronic hypercapnia;
- patients undergoing bilobectomy or pneumonectomy
About this study
Official title: Effects of Permissive Hypercapnia During Lung Surgery on Inflammatory Biomarkers in Serum and Bronchoalveolar Lavage Fluid: A Randomized Controlled Trial
The primary objective was to evaluate the effects of permissive hypercapnia on inflammatory biomarkers in bronchoalveolar lavage fluid and serum during one-lung ventilation. The secondary objective was to assess the influence of different ventilation modes on these inflammatory responses.
Methods: Forty patients undergoing elective lung surgery requiring OLV were prospectively enrolled an allocated to either a normocapnic (n=20) or hypercapnic group group (n=20). BAL concentrations of TNF-α, IL-1β, IL-6, and IL-8 were measured before and after intervention. Serum IL-6, C-reactive protein (CRP), and leukocyte counts were also assessed. Patients were further stratified according to ventilation mode (PC or VC).
Outcome measures: Primary outcome: change of bronchoalveolar lavage (BAL) levels of preselected biomarkers for inflammation (TNF-α , IL-1β, IL-6, and IL-8) as well as in serum (IL-6, CRP, and WBC) between the normocapnic and hypercapnic groups during one-lung ventilation. Secondary outcome: whether the inflammatory response differed according to the ventilation mode (pressure-controlled versus volume-controlled ventilation).
Read the detailed description
Following admission to the preoperative area, demographic and clinical data were recorded, including age, sex, height, body weight, ideal body weight (IBW), comorbidities, smoking status, and ASA physical status classification. An arterial catheter was inserted before induction of anesthesia to allow continuous invasive blood pressure monitoring and arterial blood gas analysis.
Patients were pre-oxygenated with 100% oxygen for 3-5 minutes before induction of anesthesia. General anesthesia was induced and maintained using target-controlled infusion (TCI) of propofol with target effect-site concentration (Ceff) of 2.0-6.0 ng/ml (Schnider model) and remifentanil with a target-effect site concentration (Ceff) of 2.0-8.0 ng/ml (Minto model). Neuromuscular blockade was achieved with rocuronium bromide (0.6 mg/kg). The depth of anesthesia was monitored using the Bispectral Index (BIS) and were maintained between 40 and 60.
Following induction, all patients were intubated with a double-lumen endotracheal tube (Rüsch, Bronchopart, Teleflex, USA). Correct placement of the tube was confirmed by fiberoptic bronchoscopy immediately after intubation and reassessed following lateral positioning.
During two-lung ventilation, patients in the VC group received a tidal volume of 7 mL/kg IBW. During OLV, tidal volume was reduced to 5 mL/kg IBW. For patients ven-tilated using the PC mode, inspiratory pressure was adjusted to achieve equivalent tidal volumes. PEEP was initially set at 5 cm H₂O and remained unchanged unless hypoxemia occurred. The fraction of inspired oxygen (FiO₂) was initially set at 1.0 and reduced to 0.5 after initiation of OLV. The intended strategy was to minimize FiO2 at 0.5; however, FiO2 was increased when significant hypoxemia persisted for several minutes. Prior to and following the initiation of OLV, an alveolar recruitment maneuver was applied (manual inflations for 10-40 seconds to achieve a peak airway pressure of 30-40 cmH20). In cases of severe hypoxemia (<88%), the first intervention was an increase in the inspired oxygen fraction (FiO₂). If adequate oxygenation was not achieved, further ventilatory adjustments were implemented, including increases in PEEP, and inspiratory time, as well as application of the recruitment maneuver according to the clinical situation and ventilatory parameters.
Respiratory rate was adjusted to maintain the predefined PaCO₂ targets:
- Normocapnic group: 35-45 mmHg
- Hypercapnic group: 55-75 mmHg An inspiratory-to-expiratory (I:E) ratio ranging from 1:2 to 1:1 was maintained throughout the procedure. Throughout the surgical procedure, patients were monitored using a 5-lead electrocardiogram (ECG), invasive blood pressure measurement, heart rate, and depth of anesthesia using the Bispectral Index (BIS).
Ventilatory parameters, including tidal volume (TV), fraction of inspired oxygen (FiO2), respiratory rate (RR), SpO2, expired carbon dioxide (EtCO2), PEEP, peak (Ppeak), inspiratory pressure above PEEP (Pinsp), plateau airway pressure (Pplat), driving pres-sure (ΔP) - calculated as the difference between Pplat and PEEP), and the dynamic com-pliance, together with arterial blood gas parameters, were assessed at predefined time points.
In VC subgroup, Ppeak and Pplat were recorded. In PC subgroup, the set inspiratory pressure above PEEP (Pinsp) was recorded, as it represented the target inspiratory airway pressure. In PC mode, Pinsp was used as a surrogate for inspiratory airway pressure under controlled mechanical ventilation.
The predefined time points were: prior to anesthesia induction (Tbas), after induction, after intubation and initiation of two-lung ventilation (T1), after positioning in the lateral decubitus position (T2), 15 minutes from the onset of OLV (T3), 1 hour after the onset of OLV (T4), and after conversion back to two-lung ventilation in the supine position (T5).
2.7. Bronchoalveolar Lavage Fluid and Biomarker Analysis Prior to initiation of one-lung ventilation and following the return to two-lung ven-tilation and lung re-expansion, bronchoalveolar lavage (BAL) fluid was collected from two bronchopulumonary segments (the same segments before and after intervention) of both the collapsed and ventilated lungs. Samples from both lungs were pooled and analyzed together. BAL was performed using fiberoptic bronchoscope and 60 ml of sterile saline, with gentle aspiration under negative pressure of -50 cmH20. The recovered lavage fluid was collected, and 10-15 ml of BAL fluid was obtained for laboratory analysis. Due to variability in recovery volume, BAL samples were analyzed without normalization to the initial instilled lavage volume. BAL fluid was centrifuged at 1500 rpm for 15 minutes at room temperature. The supernatant was frozen and stored at -80 °C and interleukin levels were determined enzyme-linked immunosorbent assay (ELISA) with commercially available kits (FineTest,Wuhan China) according to the manufacturer's instructions. All samples were analyzed in the same assay run. The detection limits of the kits were as follows: TNF -α 3.8 pg/ml, IL-1β 1.56 pg/ml, IL-6 2.5 pg/ml, and IL-8 7.8 pg/ml.
Peripheral venous blood samples (10 ml) were obtained at the beginning and end of surgery for the measurement of serum leukocyte count (WBC), C-reactive protein (CRP) and IL-6 levels. At the end of the procedure, all patients were extubated in the operating room and transferred either to the intensive care unit (ICU) or to the surgical ward based on the clinician's judgment.
Perioperative blood samples and BAL fluid samples were analyzed at the Central Laboratory of the University Clinical Center Niš and the Laboratory for Functional Ge-nomics and Proteomics, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš.
The duration of the surgery and anesthesia, duration of OLV, intraoperative fluid administration, urine output, and intraoperative blood loss were recorded. Potential adverse effects associated with hypercapnia were monitored, including postoperative visual disturbances, the occurrence of tachycardia and arrhythmias, postoperative emo-tional dysfunction, agitation, disorientation, panic symptoms, and convulsive seizures.
No protocol deviations were recorded during the study period.
- Conditions
- Thoracic Surgery
- Being tested
- Allowed permissive hypercapnia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Allowed permissive hypercapniaOther
| Study group | Role | What they receive |
|---|---|---|
| Permissive hypercapnia group | Experimental | The permissive hypercapnia during one-lung ventilation was used. The target CO2 values were 55-75momHg. Then the patients were divided into volume-controlled mode of ventilation or pressure-controlled mode. Receives: Other: Allowed permissive hypercapnia |
| Normocapnic group | Active comparator | Normocapnia during protective one-lung ventilation was used. And the patients were further divided in volume-controlled or pressure-controlled mode of ventilation Receives: Other: Allowed permissive hypercapnia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect of permissive hypercapnia on the inflammatory response during one-lung ventilation
The primary outcome of the study was to evaluate the effect of permissive hypercapnia on the inflammatory response during one-lung ventilation by comparing a prespecified panel of inflammatory biomarkers between the normocapnic and hypercapnic groups. The primary outcome measures included BAL concentrations of TNF-α , IL-1β, IL-6, and IL-8, together with serum IL-6, CRP, and WBC count, measured at predefined sampling time points.
Measured: After induction of anesthesia and at the end of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2026
- Study start1 Jun 2015
- Primary completion20 Feb 2026
- Study completion28 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thoracic SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomization was performed in two consecutive stages using sequentially num-bered, opaque, sealed envelope. In the first stage, patients were randomly allocated in a 1:1 ratio to the normocapnia (n=20) or the hypercapnia group (n=20). In the second stage, patients within each group were further randomized in a 1:1 ratio to receive either pres-sure-controlled ventilation (PCV) or volume-controlled ventilation (VCV) using the same allocation procedure.
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nis
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Milena Stojanovic, University of Nis
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07749456
- Sponsor's protocol ID
- 3856/ and12-3102-1/2-2
- Status last verified
- Jul 2026
- First submitted
- 29 Jul 2026
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because no data sharing plan has been established.
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Permissive Hypercapnia During Lung Surgery on Inflammatory Biomarkers in Serum and Bronchoalveolar Lavage Fluid: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07749456
- Acronym / sponsor ID
- 3856/ and12-3102-1/2-2
- Conditions
- Thoracic Surgery
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University of NisUniversity, hospital or other
- Study start
- 1 Jun 2015 (actual)
- Primary completion
- 20 Feb 2026 (actual)
- Study completion
- 28 Feb 2026 (actual)
- First posted
- 6 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective was to evaluate the effects of permissive hypercapnia on inflammatory biomarkers in bronchoalveolar lavage fluid and serum during one-lung ventilation. The secondary objective was to assess the influence of different ventilation modes on these inflammatory responses.
Methods: Forty patients undergoing elective lung surgery requiring OLV were prospectively enrolled an allocated to either a normocapnic (n=20) or hypercapnic group group (n=20). BAL concentrations of TNF-α, IL-1β, IL-6, and IL-8 were measured before and after intervention. Serum IL-6, C-reactive protein (CRP), and leukocyte counts were also assessed. Patients were further stratified according to ventilation mode (PC or VC).
Outcome measures: Primary outcome: change of bronchoalveolar lavage (BAL) levels of preselected biomarkers for inflammation (TNF-α , IL-1β, IL-6, and IL-8) as well as in serum (IL-6, CRP, and WBC) between the normocapnic and hypercapnic groups during one-lung ventilation. Secondary outcome: whether the inflammatory response differed according to the ventilation mode (pressure-controlled versus volume-controlled ventilation).
Detailed description
Following admission to the preoperative area, demographic and clinical data were recorded, including age, sex, height, body weight, ideal body weight (IBW), comorbidities, smoking status, and ASA physical status classification. An arterial catheter was inserted before induction of anesthesia to allow continuous invasive blood pressure monitoring and arterial blood gas analysis.
Patients were pre-oxygenated with 100% oxygen for 3-5 minutes before induction of anesthesia. General anesthesia was induced and maintained using target-controlled infusion (TCI) of propofol with target effect-site concentration (Ceff) of 2.0-6.0 ng/ml (Schnider model) and remifentanil with a target-effect site concentration (Ceff) of 2.0-8.0 ng/ml (Minto model). Neuromuscular blockade was achieved with rocuronium bromide (0.6 mg/kg). The depth of anesthesia was monitored using the Bispectral Index (BIS) and were maintained between 40 and 60.
Following induction, all patients were intubated with a double-lumen endotracheal tube (Rüsch, Bronchopart, Teleflex, USA). Correct placement of the tube was confirmed by fiberoptic bronchoscopy immediately after intubation and reassessed following lateral positioning.
During two-lung ventilation, patients in the VC group received a tidal volume of 7 mL/kg IBW. During OLV, tidal volume was reduced to 5 mL/kg IBW. For patients ven-tilated using the PC mode, inspiratory pressure was adjusted to achieve equivalent tidal volumes. PEEP was initially set at 5 cm H₂O and remained unchanged unless hypoxemia occurred. The fraction of inspired oxygen (FiO₂) was initially set at 1.0 and reduced to 0.5 after initiation of OLV. The intended strategy was to minimize FiO2 at 0.5; however, FiO2 was increased when significant hypoxemia persisted for several minutes. Prior to and following the initiation of OLV, an alveolar recruitment maneuver was applied (manual inflations for 10-40 seconds to achieve a peak airway pressure of 30-40 cmH20). In cases of severe hypoxemia (<88%), the first intervention was an increase in the inspired oxygen fraction (FiO₂). If adequate oxygenation was not achieved, further ventilatory adjustments were implemented, including increases in PEEP, and inspiratory time, as well as application of the recruitment maneuver according to the clinical situation and ventilatory parameters.
Respiratory rate was adjusted to maintain the predefined PaCO₂ targets:
- Normocapnic group: 35-45 mmHg
- Hypercapnic group: 55-75 mmHg An inspiratory-to-expiratory (I:E) ratio ranging from 1:2 to 1:1 was maintained throughout the procedure. Throughout the surgical procedure, patients were monitored using a 5-lead electrocardiogram (ECG), invasive blood pressure measurement, heart rate, and depth of anesthesia using the Bispectral Index (BIS).
Ventilatory parameters, including tidal volume (TV), fraction of inspired oxygen (FiO2), respiratory rate (RR), SpO2, expired carbon dioxide (EtCO2), PEEP, peak (Ppeak), inspiratory pressure above PEEP (Pinsp), plateau airway pressure (Pplat), driving pres-sure (ΔP) - calculated as the difference between Pplat and PEEP), and the dynamic com-pliance, together with arterial blood gas parameters, were assessed at predefined time points.
In VC subgroup, Ppeak and Pplat were recorded. In PC subgroup, the set inspiratory pressure above PEEP (Pinsp) was recorded, as it represented the target inspiratory airway pressure. In PC mode, Pinsp was used as a surrogate for inspiratory airway pressure under controlled mechanical ventilation.
The predefined time points were: prior to anesthesia induction (Tbas), after induction, after intubation and initiation of two-lung ventilation (T1), after positioning in the lateral decubitus position (T2), 15 minutes from the onset of OLV (T3), 1 hour after the onset of OLV (T4), and after conversion back to two-lung ventilation in the supine position (T5).
2.7. Bronchoalveolar Lavage Fluid and Biomarker Analysis Prior to initiation of one-lung ventilation and following the return to two-lung ven-tilation and lung re-expansion, bronchoalveolar lavage (BAL) fluid was collected from two bronchopulumonary segments (the same segments before and after intervention) of both the collapsed and ventilated lungs. Samples from both lungs were pooled and analyzed together. BAL was performed using fiberoptic bronchoscope and 60 ml of sterile saline, with gentle aspiration under negative pressure of -50 cmH20. The recovered lavage fluid was collected, and 10-15 ml of BAL fluid was obtained for laboratory analysis. Due to variability in recovery volume, BAL samples were analyzed without normalization to the initial instilled lavage volume. BAL fluid was centrifuged at 1500 rpm for 15 minutes at room temperature. The supernatant was frozen and stored at -80 °C and interleukin levels were determined enzyme-linked immunosorbent assay (ELISA) with commercially available kits (FineTest,Wuhan China) according to the manufacturer's instructions. All samples were analyzed in the same assay run. The detection limits of the kits were as follows: TNF -α 3.8 pg/ml, IL-1β 1.56 pg/ml, IL-6 2.5 pg/ml, and IL-8 7.8 pg/ml.
Peripheral venous blood samples (10 ml) were obtained at the beginning and end of surgery for the measurement of serum leukocyte count (WBC), C-reactive protein (CRP) and IL-6 levels. At the end of the procedure, all patients were extubated in the operating room and transferred either to the intensive care unit (ICU) or to the surgical ward based on the clinician's judgment.
Perioperative blood samples and BAL fluid samples were analyzed at the Central Laboratory of the University Clinical Center Niš and the Laboratory for Functional Ge-nomics and Proteomics, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš.
The duration of the surgery and anesthesia, duration of OLV, intraoperative fluid administration, urine output, and intraoperative blood loss were recorded. Potential adverse effects associated with hypercapnia were monitored, including postoperative visual disturbances, the occurrence of tachycardia and arrhythmias, postoperative emo-tional dysfunction, agitation, disorientation, panic symptoms, and convulsive seizures.
No protocol deviations were recorded during the study period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Randomization was performed in two consecutive stages using sequentially num-bered, opaque, sealed envelope. In the first stage, patients were randomly allocated in a 1:1 ratio to the normocapnia (n=20) or the hypercapnia group (n=20). In the second stage, patients within each group were further randomized in a 1:1 ratio to receive either pres-sure-controlled ventilation (PCV) or volume-controlled ventilation (VCV) using the same allocation procedure.
| Arm | Type | Receives |
|---|---|---|
| Permissive hypercapnia group | Experimental | Other: Allowed permissive hypercapniaThe permissive hypercapnia during one-lung ventilation was used. The target CO2 values were 55-75momHg. Then the patients were divided into volume-controlled mode of ventilation or pressure-controlled mode. |
| Normocapnic group | Active comparator | Other: Allowed permissive hypercapniaNormocapnia during protective one-lung ventilation was used. And the patients were further divided in volume-controlled or pressure-controlled mode of ventilation |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Eligible participants were aged 18-85 years,
- classified as American Society of Anesthesiologists (ASA) physical status I-III, --scheduled for procedures expected to last at least 60 minutes, with anticipated OLV for the the majority of the intraoperative period.
Key exclusion criteria (10 listed)
- body mass index (BMI) > 35 kg/m2;
- impaired pulmonary function (vital capacity of forced expiratory volume in 1 second (FEV1) < 50% of predicted values);
- chronic infection;
- intracranial hypertension;
- prior intracranial hemorrhage;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Allowed permissive hypercapnia | Other | Normocapnic group, Permissive hypercapnia group |
Primary outcome
Effect of permissive hypercapnia on the inflammatory response during one-lung ventilation
Time frame: After induction of anesthesia and at the end of surgery
The primary outcome of the study was to evaluate the effect of permissive hypercapnia on the inflammatory response during one-lung ventilation by comparing a prespecified panel of inflammatory biomarkers between the normocapnic and hypercapnic groups. The primary outcome measures included BAL concentrations of TNF-α , IL-1β, IL-6, and IL-8, together with serum IL-6, CRP, and WBC count, measured at predefined sampling time points.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because no data sharing plan has been established.
Related trials for Thoracic Surgery
Active, not recruitingPhase 2
Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
RecruitingPhase 3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Non Small Cell Lung Cancer
Not yet recruiting
Effect of Warm Footbath Combined With Relaxation Exercise on Pain and Anxiety During Chest Tube Removal After Cardiac Surgery
Chest Tube Removal
RecruitingPhase 3
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Lung Non-Small Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Allowed permissive hypercapnia in people with Thoracic Surgery, run by University of Nis.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect of permissive hypercapnia on the inflammatory response during one-lung ventilation (time frame: After induction of anesthesia and at the end of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.